摘要
目的探讨不同疗效评价标准对结肠癌肝脏转移瘤的疗效评价是否具有一致性。方法收集2010年12月-2012年12月我院临床资料完整且手术病理证实的结肠癌肝脏转移瘤患者68例,治疗前2周内及治疗6周后分别行多层螺旋CT(multi-slice spiral computed tomography,MSCT)增强扫描,通过西门子软件半自动处理技术对病灶进行测量后用实体瘤疗效评价的WHO标准、RECIST1.0标准和RECIST1.1标准进行评估。结果通过Spearman相关性分析,WHO标准与RECIST1.0标准、WHO标准与RECIST1.1标准,RECIST1.0标准与RECIST1.1标准相关系数分别为0.834、0.827、0.843,P均<0.05。结论 WHO标准、RECIST1.0标准和RECIST1.1标准具有较好的一致性,RECIST 1.1标准更适合对结肠癌肝脏转移瘤患者进行疗效评价。
Objective To study the consistency of different curative effect assessment criteria for liver metastasis of colon cancer. Methods Clinical data about 68 patients with surgery and biopsy-confirmed liver metastasis of colon cancer admitted to our hospital from 2010 to 2012 were retrospectively analyzed. The patients underwent enhanced multi-slice spiral CT scanning 2 weeks before and 6 weeks after treatment, respectively. The curative effect for solid tumor was assessed according to the WHO, RECIST1.0, and RECIST1.1 criteria using the Siemens software. Results Spearman correlation analysis showed that the coefficient for the WHO and RECIST1.0 criteria, RECIST1.1 criteria, and RECISTI.1 criteria was 0.834, 0.827, and 0.843, respectively （P 〈 0.05）.Conclusion The consistency of WHO, RECIST1.0 and RECIST1.1 criteria is quite good. However, the RECIST1.1 criteria are more suitable for the curative effect assessment in patients with liver metastasis of colon cancer.
出处
《解放军医学院学报》
CAS
2014年第1期25-27,共3页
Academic Journal of Chinese PLA Medical School
关键词
实体瘤的疗效评价标准
多层螺旋CT
转移瘤
response evaluation criteria in solid tumor
multi-slice spiral computed tomography
metastases
